Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 9/20 | 0.43 |
| ▸ | HTR2B | P41595 | 6/20 | 0.42 |
| ▸ | HTR2A | P28223 | 4/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL324675 | 0.96 | HTR2C (0.43) | MEN1KMT2AHTR2CHTR2BHTR2A | |
| SCHEMBL7563619 | 0.83 | HTR2C (0.40) | MEN1KMT2AHTR2CHTR2BHTR2A | |
| SCHEMBL20348840 | 0.81 | SLC6A2 (0.46) | HTR2CHTR2BHTR2A | |
| SCHEMBL839081 | 0.80 | MEN1 (0.50) | MEN1KMT2AHTR2CHTR2BHTR2A | |
| SCHEMBL726241 | 0.80 | MAOB (0.62) | MEN1KMT2AHTR2CHTR2BHTR2A | |
| SCHEMBL147285 | 0.79 | SLC6A4 (0.44) | MEN1KMT2AHTR2C | |
| SCHEMBL21535613 | 0.79 | MAOB (0.44) | HTR2CHTR2BHTR2AMAOB | |
| SCHEMBL21668620 | 0.79 | SLC6A3 (0.48) | HTR2CHTR2BHTR2AMAOB | |
| SCHEMBL25943717 | 0.79 | HTR2C (0.66) | MEN1KMT2AHTR2CHTR2BHTR2A | |
| SCHEMBL27533682 | 0.78 | ALDH1A1 (0.47) | MEN1KMT2AHTR2CHTR2BHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10968163-B2 | Alpha-truxillic acid derivatives and pharmaceutical compositions thereof | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2021-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10968163-B2 | Alpha-truxillic acid derivatives and pharmaceutical compositions thereof | FABP1, FABP2, FABP4 | MEN1 4877/4885KMT2A 4537/4885HTR2C 724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.